Try our mobile app

Switch to company model in classical logic    *

General information

Country: BRITAIN

Sector: Biotechnology

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company`s lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Website: achillestx.com




Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.0% (LTM)

Entry Point: Share price is 7.2% higher than minimum and 94.3% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: ACHL
Share price, USD:  (+3.0%)0.8037
year average price 0.9549  


year start price 0.9601 2023-05-08

max close price 1.5700 2024-02-28

min close price 0.7500 2024-04-30

current price 0.8037 2024-05-06
Common stocks: 40 771 001

Dividend Yield:  0.0%
Last revenue growth (y/y):  ---
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 33
Net Debt ($m): -225
EV (Enterprise Value): -192
Price to Book: 0.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-06-12GlobeNewsWire

Achilles Therapeutics to Present at Upcoming Conferences
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ACHL ACHL ACHL ACHL ACHL ACHL
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-04-04 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
acceptedDate 2024-04-04 08:12:35 2023-09-29 20:00:00 2023-06-30 00:00:00 2023-03-31 00:00:00 2022-12-31 00:00:00 2022-09-30 00:00:00
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 0 0 0 0 0
costOfRevenue 1M 1M 1M 0 0 0
grossProfit -1M -1M -1M 0 0 0
grossProfitRatio 0 0 0 0 0 0
researchAndDevelopmentExpenses 16M 15M 14M 14M 19M 11M
generalAndAdministrativeExpenses 4M 4M 4M 5M 4M 5M
sellingAndMarketingExpenses -1M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 2M 4M 4M 5M 4M 5M
otherExpenses 1M 2M 1M 1M -1M 0
operatingExpenses 19M 19M 18M 19M 23M 16M
costAndExpenses 20M 19M 18M 19M 23M 16M
interestIncome 0 0 0 0 0 0
interestExpense 0 0 0 -1M 1M -4M
depreciationAndAmortization 1M 1M 1M 0 -2M 0
ebitda -19M -19M -18M -19M -23M -16M
ebitdaratio 0 0 0 0 0 0
operatingIncome -20M -19M -18M -19M -23M -16M
operatingIncomeRatio 0 0 0 0 0 0
totalOtherIncomeExpensesNet 1M 2M 1M 1M -1M 4M
incomeBeforeTax -18M -17M -17M -17M -24M -12M
incomeBeforeTaxRatio 0 0 0 0 0 0
incomeTaxExpense 509 393 -24 000 -34 000 44 000 41 000 41 000
netIncome -19M -17M -17M -18M -24M -12M
netIncomeRatio 0 0 0 0 0 0
eps -0.470 -0.420 -0.420 -0.440 -0.610 -0.320
epsdiluted -0.470 -0.420 -0.420 -0.440 -0.610 -0.320
weightedAverageShsOut 40M 40M 40M 40M 39M 39M
weightedAverageShsOutDil 40M 40M 40M 40M 39M 39M
link Link
finalLink Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ACHL ACHL ACHL ACHL ACHL ACHL
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-04-04 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
acceptedDate 2024-04-04 08:12:35 2023-09-29 20:00:00 2023-06-30 00:00:00 2023-03-31 00:00:00 2022-12-31 00:00:00 2022-09-30 00:00:00
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 132M 140M 144M 158M 173M 180M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 132M 140M 144M 158M 173M 180M
netReceivables 10M 10M 23M 0 16M 0
inventory 1.000 -10M -23M 0 5M 0
otherCurrentAssets 4M 15M 31M 27M 3M 19M
totalCurrentAssets 146M 155M 175M 185M 197M 199M
propertyPlantEquipmentNet 14M 17M 19M 19M 20M 26M
goodwill 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets -1.000 -33 000 -33 000 0 0 0
longTermInvestments 33 000 33 000 33 000 0 0 0
taxAssets 41 000 185 000 185 000 185 000 251 000 26 000
otherNonCurrentAssets 2M 3M 3M 3M 3M 3M
totalNonCurrentAssets 16M 20M 23M 22M 24M 29M
otherAssets 1.000 0 0 0 0 0
totalAssets 161M 175M 198M 208M 220M 227M
accountPayables 6M 5M 7M 8M 5M 8M
shortTermDebt 4M 5M 5M 4M 4M 4M
taxPayables 0 0 7000.000 304 000 326 000 59 000
deferredRevenue -6M 0 0 0 0 0
otherCurrentLiabilities 13M 8M 8M 6M 9M 8M
totalCurrentLiabilities 17M 18M 19M 18M 18M 19M
longTermDebt 1M 3M 4M 4M 4M 5M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 1M 941 000 974 000 954 000 933 000 -6M
totalNonCurrentLiabilities 2M 4M 5M 5M 5M 6M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 1M 7M 9M 8M 9M 9M
totalLiabilities 19M 22M 24M 22M 23M 25M
preferredStock 0 0 0 0 0 0
commonStock 182 000 54 000 54 000 54 000 54 000 54 000
retainedEarnings -260M -241M -225M -208M -190M -166M
accumulatedOtherComprehensiveIncomeLoss -13M -19M -14M -18M -22M -38M
othertotalStockholdersEquity 415M 414M 412M 411M 409M 407M
totalStockholdersEquity 142M 153M 174M 185M 197M 203M
totalEquity 142M 153M 174M 185M 197M 203M
totalLiabilitiesAndStockholdersEquity 161M 175M 198M 208M 220M 227M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 161M 175M 198M 208M 220M 227M
totalInvestments 33 000 33 000 33 000 0 0 0
totalDebt 5M 7M 9M 8M 9M 9M
netDebt -127M -133M -135M -151M -165M -171M
link Link
finalLink Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2022 q4 2022 q2 2022 q1
date 2023-12-31 2023-09-30 2023-06-30 2022-12-31 2022-06-30 2022-03-31
symbol ACHL ACHL ACHL ACHL ACHL ACHL
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-04-04 2023-09-30 2023-06-30 2023-03-07 2022-06-30 2022-03-31
acceptedDate 2024-04-04 08:12:35 2023-09-28 20:00:00 2023-06-29 20:00:00 2023-03-07 16:37:31 2022-06-30 00:00:00 2022-03-31
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q4 Q2 Q1
netIncome -19M -17M -16 846 53M -17M -17M
depreciationAndAmortization 1M 1M 1253.000 -3M 916 000 1M
deferredIncomeTax -4M -2M 0 0 0 0
stockBasedCompensation 1M 1608.000 1701.000 -5M 2M 2M
changeInWorkingCapital 2M 15M 0 7M -2M -6M
accountsReceivables 0 0 0 0 0 0
inventory 0 0 0 0 0 0
accountsPayables -146 000 0 0 -5M 3M 423 000
otherWorkingCapital 2M 15M 0 11M -5M 0
otherNonCashItems 4M 4M -3517.000 -60M 440 000 -376 000
netCashProvidedByOperatingActivities -14M 1M -17 409 -8M -16M -21M
investmentsInPropertyPlantAndEquipment -45 608 -61 383 -537.000 6M -2M -2M
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites 0 0 0 -8M 0 0
netCashUsedForInvestingActivites -45 608 -61 383 -537.000 -2M -2M -2M
debtRepayment 0 0 0 0 0 0
commonStockIssued -4.861 8033.417 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 0 8.000 0 1000.000 0 0
netCashUsedProvidedByFinancingActivities -4.861 8033.417 0 1000.000 0 0
effectOfForexChangesOnCash 6M -4520.000 3197.000 23M -17M -7M
netChangeInCash -9M -4M -14 749 13M -35M -29M
cashAtEndOfPeriod 132M 140M 143 744 215M 202M 237M
cashAtBeginningOfPeriod 140M 144M 158 493 202M 237M 266M
operatingCashFlow -14M 1M -17 409 -8M -16M -21M
capitalExpenditure -45 608 -61 383 -537.000 6M -2M -2M
freeCashFlow -14M 1M -17 946 -3M -18M -22M
link Link Link
finalLink Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-04-04 10:45 ET
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
2024-04-04 10:30 ET
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
2024-04-04 10:30 ET
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
2024-02-05 12:00 ET
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
2023-12-18 12:00 ET
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
2023-12-18 12:00 ET
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
2023-11-13 21:30 ET
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
2023-09-22 20:30 ET
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
2023-08-04 11:00 ET
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
2023-06-12 12:00 ET
Achilles Therapeutics to Present at Upcoming Conferences
2023-06-12 12:00 ET
Achilles Therapeutics to Present at Upcoming Conferences
2023-05-10 11:15 ET
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
2023-05-10 11:00 ET
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
2023-05-10 11:00 ET
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
2023-04-25 22:00 ET
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
2023-04-25 11:00 ET
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
2023-04-25 11:00 ET
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
2023-04-17 12:00 ET
Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
2023-03-07 12:00 ET
Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights
2022-12-20 13:30 ET
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-06 11:00 ET
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
2022-12-06 11:00 ET
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
2022-11-30 23:05 ET
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
2022-11-30 23:05 ET
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
2022-11-22 13:00 ET
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
2022-11-22 13:00 ET
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
2022-11-08 12:00 ET
Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
2022-10-06 12:30 ET
Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
2022-10-06 12:30 ET
Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
2022-08-09 11:00 ET
Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
2022-07-21 12:00 ET
Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing
2022-07-21 12:00 ET
Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing
2022-06-30 12:00 ET
Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board
2022-06-30 12:00 ET
Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board
2022-06-21 12:30 ET
Achilles Therapeutics Recognized with the 2022 PING Innovation Award
2022-06-21 12:30 ET
Achilles Therapeutics Recognized with the 2022 PING Innovation Award
2022-05-10 11:00 ET
Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
2022-05-09 11:00 ET
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma
2022-05-09 11:00 ET
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma
2022-05-04 12:00 ET
Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
2022-05-03 12:00 ET
Achilles Therapeutics to Present at Upcoming Conferences
2022-04-12 11:30 ET
Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US
2022-04-12 11:30 ET
Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US
2022-04-12 11:30 ET
The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy Powerhouse
2022-04-05 12:00 ET
Achilles Therapeutics to Present at Upcoming Conferences
2022-04-04 12:00 ET
Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting
2022-04-04 12:00 ET
Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting
2022-03-08 13:00 ET
Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
2022-03-01 14:00 ET
Achilles Therapeutics Selects Netrality’s 401 North Broad for United States Headquarters
2022-03-01 12:02 ET
Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights
2022-03-01 12:02 ET
Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights
2022-02-07 12:30 ET
Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.
2022-02-07 12:30 ET
Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.
2022-01-13 12:30 ET
Achilles Therapeutics Provides Business Update and Outlook for 2022
2022-01-13 12:30 ET
Achilles Therapeutics Provides Business Update and Outlook for 2022
2021-12-21 13:00 ET
Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-20 13:00 ET
Achilles Therapeutics Added to the NASDAQ Biotechnology Index
2021-12-09 12:00 ET
Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens
2021-11-12 12:00 ET
Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS™ Process 2 Manufacturing
2021-11-12 12:00 ET
Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS™ Process 2 Manufacturing
2021-11-10 13:15 ET
Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies
2021-11-09 13:00 ET
Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights
2021-11-09 13:00 ET
Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights
2021-10-22 11:30 ET
Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tum...
2021-10-22 11:30 ET
Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tum...
2021-10-12 12:00 ET
Achilles Therapeutics to join the Northern Alliance Advanced Therapy Treatment Centre consortium
2021-10-12 12:00 ET
Achilles Therapeutics to join the Northern Alliance Advanced Therapy Treatment Centre consortium
2021-10-01 12:00 ET
Achilles Therapeutics to Present at Upcoming Scientific Congresses
2021-09-02 12:30 ET
Achilles Therapeutics to Present at Upcoming Investor Conferences
2021-08-25 12:00 ET
Achilles Therapeutics Announces Grant of US and European Patents
2021-08-25 12:00 ET
Achilles Therapeutics Announces Grant of US and European Patents
2021-08-10 11:00 ET
Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights
2021-08-10 11:00 ET
Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights
2021-07-01 12:00 ET
Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer
2021-07-01 12:00 ET
Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer
2021-06-04 13:00 ET
Achilles Therapeutics Details Phase I/IIa Clinical Trial Design of CHIRON in Patients with Advanced Non-Small Cell Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
2021-06-04 13:00 ET
Achilles Therapeutics Details Phase I/IIa Clinical Trial Design of CHIRON in Patients with Advanced Non-Small Cell Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
2021-05-11 11:00 ET
Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights
2021-05-06 12:00 ET
Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium
2021-05-06 12:00 ET
Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium
2021-05-05 12:30 ET
Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference
2021-05-03 12:00 ET
Achilles Therapeutics Appoints Julie O’Neill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Advisory Board
2021-05-03 12:00 ET
Achilles Therapeutics Appoints Julie O’Neill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Advisory Board
2021-04-10 12:30 ET
Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting
2021-04-10 12:30 ET
Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting
2021-04-06 20:01 ET
Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering

SEC forms

Show financial reports only

SEC form 6
2023-11-13 16:36 ET
Achilles Therapeutics plc reported for 2023 q3
SEC form 6
2023-09-22 16:42 ET
Achilles Therapeutics plc published news for 2023 q2
SEC form 6
2023-08-04 00:00 ET
Achilles Therapeutics plc reported for 2023 q2
SEC form 6
2023-06-29 16:03 ET
Achilles Therapeutics plc published news for 2023 q1